Reuters logo
Valeant Pharma's revenue falls for third straight quarter
February 28, 2017 / 12:15 PM / 7 months ago

Valeant Pharma's revenue falls for third straight quarter

Feb 28 (Reuters) - Valeant Pharmaceuticals International Inc reported a 12.9 percent fall in quarterly revenue on Tuesday, its third straight quarter of a double-digit percentage decrease, as sales declined across its businesses and realized prices fell.

Net loss attributable to Valeant widened to $515 million, or $1.47 per share in the fourth quarter ended Dec. 31, from $385 million, or $1.12 per share, a year earlier.

Revenue slipped to $2.40 billion from $2.76 billion.

Laval, Quebec-based Valeant has been trying to rebuild its business and regain investor confidence after it came under investigations over its accounting and pricing practices.

Reporting by Ankur Banerjee in Bengaluru

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below